These emerging treatments, Retatrutide, represent a remarkable advancement in treating obesity and conceivably related conditions . They all are grouped as GLP-1 pathway activators , indicating they function to replicate the endogenous GLP-1 peptide, enhancing metabolic secretion and suppressing